Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 211875
Company: AM REGENT

Products on NDA 211875

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 211875

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
07/27/2022	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211875s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211875Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/211875Orig1s000TOC.html

Labels for NDA 211875

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
07/27/2022	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211875s000lbl.pdf

Therapeutic Equivalents for NDA 211875

PACLITAXEL

POWDER;INTRAVENOUS; 100MG/VIAL
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
ABRAXANE	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	Yes	AB	021660	BRISTOL-MYERS
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	Yes	AB	211875	AM REGENT
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	No	AB	209657	CIPLA
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	No	AB	212700	HENGRUI PHARMA
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	No	AB	217877	MYLAN
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	No	AB	216355	SHUANGCHENG
PACLITAXEL	PACLITAXEL	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	Yes	AB	216338	TEVA PHARMS INC